EPIC: A Low Toxicity Treatment for Relapsing Lymphoma
Author Information
Author(s): T. Hickish, A. Roldan, D. Cunningham, J. Mansil, S. Ashley, V. Nicolson, M.E. Gore, D. Catovsky, I.E. Smith
Primary Institution: Royal Marsden Hospital
Hypothesis
Can the EPIC regimen provide effective treatment for patients with relapsed or resistant lymphoma while minimizing toxicity?
Conclusion
The EPIC regimen shows a good overall response rate of 58% with manageable toxicity in patients with relapsed or resistant lymphoma.
Supporting Evidence
- Complete response was achieved in 11 patients (28%) and partial response in 12 patients (30%).
- Patients with bulky disease and B symptoms had significantly lower response rates.
- The regimen was well tolerated with myelosuppression being the most common toxicity.
Takeaway
Doctors tested a new medicine combination called EPIC on 40 patients with lymphoma that didn't get better with other treatments, and it helped many of them feel better without making them too sick.
Methodology
The study involved treating 40 patients with relapsed or resistant lymphoma using the EPIC regimen and evaluating their responses and side effects.
Limitations
The study had a small sample size and was limited to patients who had already undergone multiple treatments.
Participant Demographics
The study included 32 patients with non-Hodgkin's lymphoma and 10 with Hodgkin's disease, with a mean age of 50 years.
Statistical Information
P-Value
{"bulky_disease":"<0.005","B_symptoms":"<0.05","response_to_prior_chemotherapy":"<0.01"}
Want to read the original?
Access the complete publication on the publisher's website